Displaying 681 - 700 of 853
| Active Ingredient | VILDAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VILDAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic cont More ... |
| Caution | Asthenia, dizziness, headache, nausea;, peripheral oedema, tremor. |
| Dose Range | 1 tablet twice daily based on patient’s current metformin dose. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ASPART |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DETEMIR |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLARGINE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes mellitus. For use in patients with Type I Diabetes. |
| Caution |
Local reactions, fat hypertrophy at injection site. Insulin glargine preparations are not bioequivalent ; dose adjustment and close metabolic monitoring is recommended if switching bet More ... |
| Dose Range | Once daily at the same time each day. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLULISINE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes mellitus. For use in patients with Type I Diabetes. |
| Caution | Local reactions, fat hypertrophy at injection site. |
| Dose Range | Immediately before meals or when necessary shortly sfter meals, according to requirements. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN ISOPHANE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus. |
| Caution | See under Insulin (lente), Zinc Suspension, Human. |
| Dose Range | See under Insulin (lente), Zinc Susp ension, Human. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN ISOPHANE | INSULIN RAPID |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus. |
| Caution | Hypoglycemia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN RAPID |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus |
| Caution | See under Insulin (lente), Zinc Suspension, Human. |
| Dose Range |
See under Insulin (lente), Zinc Suspension, Human. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULIN SYRINGE |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INSULINS |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ISOPHANE |
| Therapeutic Class | INSULINS |
| Indications | Diabetes Mellitus. |
| Caution | Hypoglycemia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LISPRO |
| Therapeutic Class | INSULINS |
| Indications | As for Insulin Glulisine. |
| Caution | As for Insulin Glulisine. |
| Dose Range |
Immediately before meals, but can alternatively be given immediately after eating if necessary . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PEN NEEDLES |
| Therapeutic Class | INSULINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NATEGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | REPAGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | Metformin/Empagliflozin |
| Therapeutic Class | Sodium Glucose Co-Transporter Inhibitor |
| Indications |
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Empagliflozin, when used in combination with metformin, is also ind More ... |
| Caution | Urinary tract infection ,Decreased vitamin B12 levels; Female genital mycotic infections ;Increased urination ;Male genital mycotic infections; Necrotizing fasciitis of the perineum (Fournier’s gangre More ... |
| Dose Range |
Empagliflozin total daily dose: 10 mg For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | DAPAGLIFLOZIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DAPAGLIFLOZIN | METFORMIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMPAGLIFLOZIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | Monotherapy or with other antidiabetic medications, including insulin, in the management of type 2 diabetes mellitus; To reduce the risk of cardiovascular death in those with type 2 diabetes mellitus More ... |
| Caution | Urinary tract infection, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, female genital mycotic infections, male genital mycotic infections, and nausea |
| Dose Range | The usual oral dose of empagliflozin is 10 mg once daily, which may be increased to 25 mg daily, if necessary. When given with metformin, empagliflozin may be given in 2 divided doses. Doses of insulin, sulfonylurea, or other insulin secretagogues may nee |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |